2,222 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Purchased by Legato Capital Management LLC

Legato Capital Management LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,222 shares of the company’s stock, valued at approximately $408,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Turn Management LLC acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at $30,045,000. Price T Rowe Associates Inc. MD grew its stake in Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after purchasing an additional 231,255 shares in the last quarter. Eventide Asset Management LLC purchased a new stake in Krystal Biotech during the 4th quarter worth about $16,932,000. TimesSquare Capital Management LLC raised its position in Krystal Biotech by 103.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 250,470 shares of the company’s stock valued at $31,073,000 after purchasing an additional 127,435 shares in the last quarter. Finally, Braidwell LP grew its position in shares of Krystal Biotech by 153.2% during the fourth quarter. Braidwell LP now owns 196,200 shares of the company’s stock worth $24,341,000 after buying an additional 118,703 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

KRYS stock traded down $1.55 during midday trading on Tuesday, hitting $198.96. The stock had a trading volume of 82,691 shares, compared to its average volume of 362,656. Krystal Biotech, Inc. has a 12-month low of $93.95 and a 12-month high of $219.34. The firm has a market cap of $5.68 billion, a PE ratio of 105.43 and a beta of 0.84. The company’s 50-day moving average price is $192.03 and its 200 day moving average price is $171.85.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. During the same quarter last year, the company posted ($1.25) earnings per share. Krystal Biotech’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 2 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares in the company, valued at $268,189,020.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KRYS. Evercore ISI raised their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Chardan Capital increased their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Citigroup reissued a “neutral” rating and issued a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, August 5th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $187.89.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).